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ABSTRACT
Background
Endothelial lipase (EL), a new member of the lipase family, has been shown to modulate
high-density lipoprotein (HDL-C) metabolism and atherosclerosis in mouse models. We
hypothesized that EL concentrations would be associated with decreased HDL-C and increased
atherosclerosis in humans.
Methods and Findings
Healthy individuals with a family history of premature coronary heart disease (n¼858) were
recruited as part of the Study of the Inherited Risk of Atherosclerosis. Blood was drawn in the
fasting state before and, in a subgroup (n ¼ 510), after administration of a single dose of
intravenous heparin. Plasma lipids were measured enzymatically, lipoprotein subclasses were
assessed by nuclear magnetic resonance, and coronary artery calcification (CAC) was quantified
by electron beam computed tomography. Plasma EL mass was measured using a newly
developed enzyme-linked immunosorbent assay. Median EL mass in pre-heparin plasma was
442 (interquartile range¼324–617) ng/ml. Median post-heparin mass was approximately 3-fold
higher, 1,313 (888–1,927) ng/ml. The correlation between pre-heparin EL mass and post-
heparin EL mass was 0.46 (p , 0.001). EL mass concentrations in both pre- and post-heparin
plasma significantly correlated with all NCEP ATPIII-defined metabolic syndrome factors: waist
circumference (r¼0.28 and 0.22, respectively, p , 0.001 for each), blood pressure (r¼0.18 and
0.24, p , 0.001 for each), triglycerides (r¼0.22, p , 0.001; and 0.13, p¼0.004), HDL cholesterol
(r¼ 0.11, p¼0.002; and 0.18, p , 0.001), and fasting glucose (r¼0.11 and 0.16, p¼0.001 for
both). EL mass in both routine (odds ratio [OR]¼1.67, p¼0.01) and post-heparin (OR¼2.42, p¼
0.003) plasma was associated with CAC as determined by ordinal regression after adjustment
for age, gender, waist circumference, vasoactive medications, hormone replacement therapy
(women), and established cardiovascular risk factors.
Conclusions
We report, to our knowledge for the first time, that human plasma EL concentrations, in both
post-heparin and routine pre-heparin plasma, are significantly associated with metabolic
syndrome features and with subclinical atherosclerosis. EL may be a pro-atherogenic factor in
humans, especially in overweight individuals and those with metabolic syndrome.
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Two members of the lipase family, lipoprotein lipase (LPL)
and hepatic lipase (HL) are known to inﬂuence plasma
lipoprotein metabolism and risk of atherosclerosis in humans
[1–5]. Endothelial lipase (EL) is a more recently discovered
member of this family of lipases [6,7]. In contrast to LPL and
HL, it is expressed in endothelial cells and, in the majority of
reports, has relatively more phospholipase activity than the
other two enzymes. Similar to HL and LPL, it is secreted and
binds to the endothelial surface. In vitro, EL effectively
hydrolyzes high-density lipoprotein (HDL) phospholipids. In
mice, EL has a major inﬂuence on HDL metabolism.
Adenovirally mediated overexpression of human EL in mice
dramatically reduced HDL cholesterol (HDL-C) concentra-
tions [6], shown to be due to rapid catabolism of HDL [8].
Transgenic overexpression of human EL was shown to reduce
HDL-C concentrations as well [9]. Conversely, antibody
inhibition of EL in mice signiﬁcantly increased HDL-C
concentrations [10], and EL knockout mice have a signiﬁcant
increase in HDL-C concentrations [9,11]. Furthermore, EL
knockout mice crossed onto the apolipoprotein E knockout
background have decreased atherosclerosis [12]. Based on
these studies in mice, it has been suggested that EL may be an
important risk factor and may affect the development of
atherosclerosis in humans.
The relationship of EL to variation in lipoprotein concen-
trations and atherosclerosis in humans has not been
reported. Several genetic association studies have suggested
that rare variants and common polymorphisms in the human
EL gene might be associated with variation in HDL-C
concentrations [11,13,14], but they have not been conclusive
and were not accompanied by direct measurement of EL
concentrations. We hypothesized that concentrations of EL
are inversely associated with HDL-C concentrations and
directly associated with the metabolic syndrome and athero-
sclerosis in humans. To test this, we developed an immuno-
assay for human EL and used it to measure EL mass
concentrations in both pre-heparin and post-heparin plasma
samples in individuals enrolled in the Study of the Inherited
Risk of Atherosclerosis (SIRCA). We determined the associ-
ation of EL concentrations with lipoprotein concentrations,
other cardiovascular risk factors and coronary artery calci-
ﬁcation (CAC), a noninvasive measure of coronary athero-
sclerosis [15–17].
Methods
Study Protocol
SIRCA is a cross-sectional study of asymptomatic individ-
uals and their families designed to investigate novel bio-
markers and genetic factors associated with coronary
atherosclerosis. The study design and initial ﬁndings have
previously been published [18,19]. Brieﬂy, persons were
eligible for SIRCA if they had a family history of premature
coronary artery disease (CAD), were free of clinical CAD, and
were men, 20–75 years of age or women, 30–75 years.
Exclusion criteria included other major CAD risk factors:
known diabetes, total cholesterol higher than 300 mg/dl,
cigarette smoking of one pack or more per day, or blood
pressure higher than 160/100 mm Hg. The University of
Pennsylvania Institutional Review Board approved the study
protocol. Informed consent was obtained from each partic-
ipant. This report focuses on 858 random unrelated
individuals from the SIRCA in whom plasma EL concen-
trations were measured.
Evaluated Parameters
Participants were assessed at the General Clinical Research
Center in the University of Pennsylvania Medical Center after
a 12-h overnight fast. A questionnaire was administered;
height, weight, waist circumference, and blood pressure were
obtained; and 30 ml of whole blood was drawn (‘‘pre-heparin’’
plasma) into EDTA-containing tubes. In a subset of individ-
uals (n ¼ 510), blood was drawn 10 min after intravenous
administration of heparin (60 units per kilogram body
weight). After the blood was centrifuged, the plasma was
removed and stored at  80 8C until use (‘‘post-heparin’’
plasma). Plasma total cholesterol, HDL cholesterol, and
triglyceride concentrations were measured enzymatically on
a Cobas Fara II (Roche Diagnostic Systems, Indianapolis,
Indiana, United States) using Sigma reagents (Sigma, St.
Louis, Missouri, United States) in a Centers for Disease
Control-standardized lipid laboratory. LDL cholesterol was
calculated using the Friedewald formula.
Post-heparin plasma samples in EDTA were analyzed for
lipoprotein subclasses by nuclear magnetic resonance (NMR)
[20–22] (LipoSciences, Raleigh, North Carolina, United
States). The NMR method uses the characteristic proton
signals broadcast by lipoprotein subclasses to determine both
the size and the quantity of each size of lipoprotein. A
summary of the reporting format can be found at http://www.
liposcience.com. The ten subclasses (and their size ranges)
routinely used are: large very low-density lipoprotein (VLDL)
(60–200 nm), intermediate VLDL (35–60 nm), small VLDL
(27–35 nm), IDL (23–27 nm), large low-density lipoprotein
(LDL) (21.3–23 nm), intermediate LDL (19.8–21.2 nm), small
LDL (18.3–19.7 nm), large HDL (8.8–13.0 nm), intermediate
HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm).
Electron beam computed tomography was performed on
an Imatron C-150 XP/LXP Evolution scanner (Imatron, San
Francisco, California, United States) connected to a Magic-
View workstation for volumetric image reconstruction.
Using ECG triggering with the individual in a supine
p o s i t i o n ,4 0c o n t i g u o u s ,3m m - t h i c ka x i a ls l i c e sw e r e
acquired just below the carina through the apex of the
heart. Global CAC scores were determined according to the
method of Agatston [23].
Sandwich Enzyme-Linked Immunosorbent Assay for
Human EL
Detailed information on the development and quality
control of the sandwich ELISA can be found in Protocol S1.
The wells of a 96-well microtiter plate were coated with rabbit
anti-human EL antibody. Various concentrations of puriﬁed
recombinant human EL in phosphate-buffered saline con-
taining 1% BSA were added to the wells as a standard. Plasma
samples were diluted 1:10 in phosphate-buffered saline and
applied to the wells. Speciﬁcally bound protein was incubated
with biotin-conjugated rabbit anti-human EL antibody,
followed by streptavidin-horseradish peroxidase conjugate,
and detection with o-phenylenediamine. The reaction was
stopped with 2.5 M sulfuric acid and the plate read at 490 nm.
A standard curve of 490 nm absorbance versus the known
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EL and Metabolic Syndromeconcentrations of EL was constructed. The concentration of
the plasma samples was determined by comparison to the
standard curve multiplied by the dilution factor. Using this
ELISA, EL mass concentrations were quantiﬁed in plasma
collected in the routine manner (‘‘pre-heparin’’ plasma) in
the full sample (n¼858) as well as in the post-heparin plasma
samples described above (n ¼ 510).
Statistical Analysis
Data are reported as median and interquartile range (IQR)
or mean 6 standard deviation for continuous variables and
as proportions for categorical variables. The distributions of
both pre-heparin and post-heparin EL mass concentrations
were highly skewed rightward, so analyses were performed on
log-transformed data. Variables were determined to be
normally distributed using the Shapiro-Wilk test. Spearman
correlations of EL mass with cardiovascular risk factors and
with concentrations of lipoprotein particles, measured by
NMR, are presented. The association of EL mass with
categorical variables was examined using Kruskal-Wallis rank
test. Data were analyzed in the total group and in men and
women separately, because the distributions of CAC, HDL,
EL, and many risk factors vary with gender [24,25]. Differ-
ences in log-transformed EL mass by gender, and cut-points
in waist circumference and other risk factors were measured
by t-test. Median CAC scores were compared across quartiles
of plasma EL (pre-heparin: 6–268, 268.5–422, 422.5–641, and
641.5–2,043; post-heparin: 102–888, 888.5–1,313, 1,313.5–
1,927, and 1,927.5–7,505) using the Wilcoxon test for trend.
Ordinal logistic regression is a method appropriate for the
analysis of CAC data that has a markedly non-normal
distribution and a signiﬁcant proportion of participants with
no detectable CAC [26]. CAC scores were divided into
ordered outcome categories (0, 1–10, 11–100, 101–400, and
.400) using published criteria [27] as described [26,28]. The
association of EL mass with CAC was assessed in multivariable
models that also included: (1) gender and age (age and age
2);
(2) established risk factors, gender, and age; and (3) waist
circumference, medications (including hormone replacement
therapy in women), established risk factors, gender, and age.
Established risk factors included total (or LDL) and HDL
cholesterol, triglycerides, systolic blood pressure, smoking
(current versus never and ex-smokers), race, exercise (none
versus any), fasting glucose, and alcohol intake (drinks per
week). The results of ordinal logistic regression are presented
as the odds ratio (OR) of being in a higher CAC category
comparing the highest quartile of EL mass to the lowest
quartile. The proportional odds assumption of ordinal
regression was satisﬁed for all models [29]. Data analysis was
performed by the authors (KOB, MR, and MW) using Stata 8.1
(Stata, College Station, Texas, United States).
Results
Characteristics of Study Participants
The characteristics of the study participants are summar-
ized in Table 1. Compared to the 2002 CDC report on the
body weight status of US adults [30], there were fewer
individuals of healthy weight and more obese individuals in
our cohort. The lipid proﬁles of our participants were similar
to those reported for 20- to 59-year-old participants in the
National Health and Nutrition Examination Survey III [31].
Distribution of EL Mass Concentrations in Pre-Heparin and
Post-Heparin Plasma
Our previous studies indicated that EL, like HL and LPL
[32], is an avid heparin-binding protein (unpublished data),
and we suspected that it would be released by injection of
heparin in humans. Indeed, a preliminary study in 60
individuals with normal lipid proﬁles indicated an approx-
imately 3- to 4-fold increase in EL mass concentrations from
pre-heparin to post-heparin plasma (unpublished data).
Interestingly, EL mass was abundant in pre-heparin plasma
of the entire SIRCA cohort (n ¼ 858), median ¼ 442 (range
324–617) ng/ml. After administration of heparin, median
plasma EL concentrations were approximately 3-fold higher
than in pre-heparin samples, 1,313 (888–1,927) ng/ml (n ¼
510). There were no signiﬁcant differences in pre-heparin EL
mass concentrations between men and women. While median
post-heparin EL concentrations were 16% lower in women,
1,165 (703–1,705) ng/ml, than men, 1,396 (944–2,031) ng/ml,
this difference could be attributed to greater weight in men.
The correlation between pre-heparin and post-heparin EL
mass was 0.46, p , 0.001. Using linear regression, pre-heparin
EL mass accounted for 15% of the variation in post-heparin
EL mass. While including age and gender added less than 1%
each, waist circumference accounted for 5% of the variation
in post-heparin EL mass.
Association of EL Mass Concentrations with Nonlipid
Cardiovascular Risk Factors
Differences in EL mass between groups in the presence and
absence of other risk factors were compared by Kruskal-Wallis
v
2 test. There were signiﬁcant positive associations between
hypertension and both pre-heparin (p ¼ 0.004) and post-
heparin EL mass (p ¼ 0.003). There were signiﬁcant negative
associations between exercise and EL mass in both pre-
heparin (p , 0.001) and post-heparin (p ¼ 0.015) plasma.
Smoking was associated with higher post-heparin EL mass (p¼
0.005).
Correlations of plasma EL mass with age, body mass index
(BMI), waist circumference, blood pressure, fasting glucose,
and the homeostasis model assessment (HOMA) index, a
Table 1. Clinical and Biochemical Characteristics of the Cohort
Characteristic Men (n ¼ 466) Women (n ¼ 392)
Median (IQR) Median (IQR)
Age 47 (41–52) 51 (45–57)
Cigarette smokers (%) 10.8 12.9
Blood pressure, systolic 129 (120–136) 125 (111–135)
Blood pressure, diastolic 79 (74–85) 75 (68–82)
BMI (kg/m
2) 27.9 (25.6–30.4) 26.4 (23.1–30.9)
Waist circumference 37.5 (35–41) 32 (29–36)
Total cholesterol (mg/dl) 205 (178–226) 209 (188–238)
LDL-cholesterol (mg/dl ) 128 (109–150) 123 (102–146)
HDL-cholesterol (mg/dl) 44 (38–50) 61 (46–70)
Triglycerides ( mg/dl ) 129 (92–176) 122 (82–156)
ApoA-l (mg/dl) 116 (102–131.5) 145 (125–164)
ApoB (mg/dl) 99 (86–114.5) 98 (82–113)
Pre-heparin EL (ng/ml) 420 (323–565) 472 (314–663)
Post-heparin EL (ng/ml) 1396 (944–2,031) 1165 (730–1,705)
DOI: 10.1371/journal.pmed.0030022.t001
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EL and Metabolic Syndromemeasure of insulin resistance [33], are shown in Table 2.
There was a signiﬁcant but modest positive correlation
between pre-heparin EL mass and age in the entire cohort
(r ¼ 0.14, p ¼ 0.004) and in women (r ¼ 0.13, p ¼ 0.013) (Table
2). There were signiﬁcant positive correlations between both
pre-heparin (r¼0.28, p , 0.001) and post-heparin (r¼0.22, p
, 0.001) EL concentrations and both BMI and waist circum-
ference, and these associations remained signiﬁcant when
each gender was examined separately (Table 2). In addition,
EL concentrations were greater in obese (BMI . 30)
compared to lean men and women in pre-heparin plasma,
575 6 364 ng/ml versus 456 6 328 ng/ml, p , 0.001, and in
post-heparin plasma, 1,820 6 1,253 ng/ml versus 1,417 6 836
ng/ml, p , 0.001. Both pre- and post-heparin EL mass were
correlated with an increased HOMA-IR score: r ¼ 0.27, p ,
0.001 and r ¼ 0.24, p , 0.001, respectively.
Association of EL Concentrations with Plasma Lipid and
Lipoprotein Concentrations
Both pre-heparin and post-heparin EL mass concentra-
tions were positively associated with aspects of an athero-
genic lipoprotein proﬁle (Table 2). In pre- and post-heparin
plasma, EL mass concentrations were signiﬁcantly positively
correlated with fasting plasma triglyceride and apolipopro-
tein B (apoB) concentrations in men and women and with
LDL-C in women but not men.
To further explore the relationship between plasma EL
mass and apoB-containing lipoproteins, we examined the
correlations between plasma EL mass and lipoprotein
particle size as determined by NMR lipoprotein analysis
(Table 3). A signiﬁcant positive correlation was found
between post-heparin EL mass and large VLDL concentra-
tions in men and women, consistent with the positive
association of EL with triglycerides. There was a very modest
association of EL mass with concentrations of intermediate-
size LDL particles in the entire group, which was not
signiﬁcant when assessed separately in men or women. There
were no other signiﬁcant associations of EL mass concen-
trations with apoB-containing lipoprotein subclasses.
There was a modest, but highly statistically signiﬁcant,
negative association between HDL-C concentrations and
both pre- and post-heparin EL concentrations (see Table 2).
EL mass concentrations in the lowest and the highest HDL
quartile were signiﬁcantly different, with the difference more
pronounced in post-heparin plasma, 1,766 6 1,231 ng/ml in
the lowest HDL quartile versus 1,342 6 917 ng/ml in the
highest (p¼0.001). Interestingly, the NMR analysis revealed a
negative association of post-heparin EL concentrations with
large HDL particles, and a positive association of EL mass
with small HDL particles (Table 3). There was no correlation
between either pre-heparin or post-heparin EL mass and
apoA-I concentrations.
Table 2. Association of EL Mass with Cardiovascular Risk Factor
Variable Total R (p-Value) Men R (p-Value) Women R (p-Value)
Pre Post Pre Post Pre Post
Age 0.14 (0.004) 0.048 (0.29) 0.08 (0.09) 0.11 (0.06) 0.13 (0.01) 0.06 (0.44)
BMI 0.28 (,0.001) 0.22 (,0.001) 0.24 (,0.001) 0.15 (0.01) 0.33 (,0.001) 0.26 (,0.001)
Waist circumference 0.28 (,0.001) 0.26 (,0.001) 0.25 (,0.001) 0.17 (,0.017) 0.38 (,0.001) 0.3 (0.001)
Blood pressure 0.18 (,0.001) 0.24 (,0.001) 0.15 (,0.001) 0.26 (,0.001) 0.21 (,0.001) 0.19 (,0.001)
Fasting glucose 0.11 (0.001) 0.16 (0.002) 0.1 (0.04) 0.14 (0.04) 0.13 (0.01) 0.19 (0.02)
HOMA-IR 0.27 (,0.001) 0.24 (,0.001) 0.22 (,0.001) 0.23 (,0.001) 0.33 (,0.001) 0.23 (0.003)
Triglycerides 0.22 (,0.001) 0.133 (0.004) 0.23 (,0.001) 0.13 (0.03) 0.22 (,0.001) 0.18 (0.016)
Total cholesterol 0.14 (,0.001) 0.11 (0.04) 0.1 (0.03) 0.1 (0.18) 0.19 (,0.001) 0.18 (0.01)
LDL-C 0.12 (,0.001) 0.07 (0.12) 0.06 (0.25) 0.01 (0.87) 0.2 (,0.001) 0.18 (0.01)
ApoB 0.22 (,0.001) 0.21 (,0.001) 0.2 (,0.001) 0.18 (0.002) 0.25 (,0.001) 0.27 (,0.001)
HDL-C  0.11 (0.002)  0.18 (,0.001)  0.13 (0.005)  0.12 (0.05)  0.1 (0.08)  0.15 (0.04)
ApoA-I  0.042 (0.23)  0.05 (0.32)  0.08 (0.075) 0.032 (0.59) 0.016 (0.8)  0.03 (0.67)
DOI: 10.1371/journal.pmed.0030022.t002
Table 3. Correlations between Post-Heparin EL Mass and Lipoprotein Subclasses Assessed by NMR
Lipoprotein Subclass Total (n ¼ 510) R (p-Value) Men (n ¼ 294) R (p-Value) Women (n ¼ 216) R (p-Value)
Small VLDL (27–35 nm) 0.06 (0.16) 0.05 (0.42) 0.1 (0.14)
Intermediate VLDL (35–60 nm) 0.04 (0.34) 0.05 (0.43) 0.07 (0.32)
Large VLDL (60–200 nm) 0.14 (0.002) 0.12 (0.04) 0.18 (0.01)
Small LDL (18.3–19.7 nm) 0.04 (0.35) 0.03 0.6) 0.04 (0.6)
Intermediate LDL (19.8–21.2 nm) 0.1 (0.03) 0.08 (0.18) 0.07 (0.34)
Large LDL (21.3–23 nm)  0.04 (0.38)  0.05 (0.46)  0.06 (0.4)
Small HDL (7.3–8.2 nm) 0.16 (,0.001) 0.17 (0.005) 0.14 (0.05)
Intermediate HDL (8.2–8.8 nm) 0.04 (0.36) 0 (0.99) 0.1 (0.15)
Large HDL (8.8–13 nm)  0.17 (,0.001)  0.17 (0.004)  0.22 (,0.001)
DOI: 10.1371/journal.pmed.0030022.t003
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EL and Metabolic SyndromeHigh triglycerides and low HDL-C are two of the criteria
used to diagnose metabolic syndrome. We examined the
correlation between EL mass and HDL-C concentrations in
participants with central obesity as deﬁned by NCEP ATPIII
metabolic syndrome waist circumference criteria (greater
than 35 inches in women and greater than 40 inches in men).
There were stronger negative correlations between post-
heparin EL mass in both men and women, r ¼  0.25, p ¼ 0.03
and r ¼  0.31, p ¼ 0.03, respectively.
Since there were signiﬁcant correlations between EL mass
and each of the metabolic syndrome parameters, we
examined differences in median post-heparin EL mass with
increasing numbers of metabolic syndrome factors present
(Figure 1). There was an additive effect of increasing numbers
of metabolic syndrome factors, with median EL mass
increasing from 328 ng/ml in individuals with no factors to
642 ng/ml in participants with all ﬁve factors present.
Association of EL Concentrations with Coronary Artery
Calcification
CAC scores increased across quartiles of both pre- and
post-heparin EL concentrations in men (for trend, p , 0.001
for both) and women (for trend, p , 0.001 for both) (Figure
2). Using multivariable ordinal regression analyses of the
entire cohort, plasma concentrations of both pre- and post-
heparin EL mass were signiﬁcantly associated with CAC after
controlling for age, gender, and established risk factors, and
after further adjustment for plasma lipids, waist circum-
ference, and vasoactive medications (Table 4). In stratiﬁed
analyses, the fourth EL quartile compared to the ﬁrst was
associated with higher CAC scores for both pre-heparin EL
mass, OR¼1.82 (conﬁdence interval [CI] 1.02–3.24, p¼0.043)
and post-heparin EL mass, OR¼7.63 (CI 2.44–23.9, p , 0.001)
in women, while in men pre-heparin EL mass, OR ¼ 1.7 (CI
1.0–2.9, p¼0.05) but not post-heparin EL mass, OR¼1.46 (CI
0.7–3.08, p ¼ 0.31) was signiﬁcantly associated with higher
CAC scores.
Discussion
We report, to our knowledge for the ﬁrst time, measure-
ment of plasma concentrations of EL mass in routine, pre-
heparin, and post-heparin plasma of human individuals.
Using this newly developed sandwich ELISA, we demonstra-
Figure 1. Pre-Heparin EL Mass Concentrations Were Determined in
Subgroups According to the Presence of Increasing Numbers of
Metabolic Syndrome Factors
There was an increase in median pre-heparin EL mass as the number of
metabolic syndrome factors increased. Median values and IQR are listed
above each box.
DOI: 10.1371/journal.pmed.0030022.g001
Figure 2. Coronary Artery Calcification Scores Were Compared across
Quartiles of Pre-Heparin EL Mass in Both Men and Women
The box represents the 25th to 75th percentile, and the line represents
the median CAC score within a given pre-heparin EL mass quartile. The
whiskers represent the fifth and 95th percentiles. The diamonds are
outliers above the 95th percentile. There was an increase in CAC scores
as EL mass increased.
DOI: 10.1371/journal.pmed.0030022.g002
Table 4. Multivariable Association of Plasma EL Concentrations with Coronary Artery Calcification
Variables Total: OR (CI) p-Value Men: OR (CI) p-Value Women: OR (CI) p-Value
Pre (n ¼ 841) Post (n ¼ 366) Pre (n ¼ 459) Post (n ¼ 209) Pre (n ¼ 382) Post (n ¼ 157)
Age, gender 2.57 (1.8–3.68) ,0.001 3.44 (1.98–5.98) ,0.001 2.44 (1.48–4.01) ,0.001 1.71 (0.85–3.46) 0.132 3.0 (1.77–5.08) ,0.001 10.42 (3.97–27.4) ,0.001
Age, gender, RF 1.75 (1.19–2.56) 0.005 2.53 (1.14–4.54) 0.002 1.74 (1.03–2.96) 0.04 1.47 (0.7–3.08) 0.312 1.89 (1.07–3.36) 0.029 5.31 (1.85–15.3) 0.002
Age, gender, RF, BMI 1.67 (1.13–2.46) 0.01 2.42 (1.34–4.37) 0.003 1.7 (1.0–2.9) 0.05 1.46 (0.7–3.08) 0.312 1.82 (1.02-–3.24) 0.043 7.63 (2.44–23.9) ,0.001
The ORs are the result of a comparison between the lowest EL quartile and the highest.
RF, risk factors: Total cholesterol, HDL-C, triglycerides, hypertension, smoking, exercise, and ethanol, glucose, waist circumference, and medication (niacin, fibrates, beta-blockers, statins, angiotensin-converting enzyme inhibitors, aspirin, and
hormone replacement therapy [in women, n ¼ 115]).
DOI: 10.1371/journal.pmed.0030022.t004
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EL and Metabolic Syndrometed that EL mass concentrations in pre-heparin plasma were
higher than those of LPL [34–37], and injection of heparin
resulted in a 3-fold increase in plasma EL mass to concen-
trations similar to those reported for HL [34,38]. Importantly,
within individuals, the pre-heparin and post-heparin EL
concentrations are signiﬁcantly correlated, suggesting that
pre-heparin EL mass may be a surrogate marker for total
vascular EL expression. Indeed, most of the associations
between post-heparin EL mass and metabolic syndrome
factors, cardiovascular risk factors, lipids, and CAC were also
found for pre-heparin concentrations. This suggests that
future studies of the association of EL mass concentrations
with cardiovascular outcomes may be able to be performed
using routine, pre-heparin plasma samples.
We previously reported that overexpression of EL in
hyperlipidemic mouse models reduced concentrations of
apoB-containing lipoproteins [39]. However, in this human
study, we found that concentrations of EL are positively
associated with plasma concentrations of LDL-C, triglycer-
ides, and apoB, but did not correlate with the number of
particles in LDL subfractions. This is in contrast to HL, which
hydrolyzes remnant lipoproteins and is negatively associated
with remnant particles and positively associated with con-
centrations of small, dense LDL particles [40]. The positive
association of EL with apoB-containing lipoproteins is most
likely the reﬂection of the concomitant increase in VLDL and
triglycerides [41] and EL mass found in obese individuals and
those with metabolic syndrome.
This is the ﬁrst study to demonstrate that, in humans, EL
plasma concentrations are negatively associated with HDL-C
concentrations. While the negative correlations found be-
tween plasma EL mass concentrations and HDL-C concen-
trations are decidedly modest, they are highly statistically
signiﬁcant. The correlation between plasma EL mass and
HDL-C may, in fact, underestimate the association of EL
activity with HDL-C, given that the EL mass assay may only
partially reﬂect the biological activity of EL. This ﬁnding is
consistent with published reports in mice that overexpression
of EL dramatically reduces HDL-C concentrations [6,9], and
either inhibition of EL or genetic deletion causes an increase
in HDL-C [9,10,11]. Furthermore, we show that EL concen-
trations are negatively associated with large HDL but
positively associated with small HDL, consistent with the
model proven in mice [8], whereby EL hydrolyzes surface
phospholipids on large HDL, creating smaller, phospholipid-
depleted HDL particles. This pattern of negative correlation
with large HDL and positive correlation with small HDL has
also been reported for HL [42]. Of signiﬁcance was the lack of
correlation between EL mass concentrations and apoA-I. This
ﬁnding is consistent with the report by Jahangiri [43] that EL
remodeling of HDL to smaller particles does not mediate
apoA-I dissociation.
The apolipoprotein content of HDL has been shown to
inﬂuence the activity of HL and EL toward HDL. Several
reports by Patsch et al. [44] and Mowri et al. [45] have
suggested that an increase in the apoA-II content increases
HL hydrolysis of the triglyceride in the larger HDL2 particle.
Recent studies by Hedrick et al. [46], using apoA-II transgenic
mice, suggest that apoA-II inhibits HL activity, but the
addition of apoA-I partially reverses this inhibition. Boucher
et al. [47] found similar results in in vitro studies, in which the
addition of apoA-II to apoA-I–containing HDL inhibited
substrate hydrolysis by increasing the afﬁnity of HL for the
HDL particle. The authors reported that the addition of
apoA-II to particles increased HDL size and induced a
conformational change in apoA-I. In contrast, Caiazza et al.
[48] used spherical HDL of identical size, containing
cholesteryl ester as the sole lipid core with phosphatidylcho-
line and apoA-I, apoA-II, or both to determine the inﬂuence
of apolipoproteins on EL activity. They found that EL
hydrolysis of phospholipids in apoA-II–containing HDL was
negligible, measurable in apoA-I–containing HDL, and great-
est in spherical HDL containing both apoA-I and apoA-II.
While the absence of triglycerides in these spherical particles
makes application to native HDL difﬁcult, it does suggest that
there are differences in the subpopulations of HDL to which
HL and EL bind.
Both Jin et al. [49] and Hirata et al. [50] reported that
stimulation of cultured endothelial cells with tumor necrosis
factor-a and interleukin 1b caused an increase in EL mRNA
expression and protein secretion. Elevated plasma concen-
trations of tumor necrosis factor-a are found in individuals
with metabolic syndrome [51]. The positive correlations
between plasma EL mass, obesity, and the other metabolic
syndrome factors provide indirect evidence of a cytokine-
mediated increase in endothelial EL protein secretion in the
setting of obesity and metabolic syndrome. The signiﬁcant
difference in EL mass between lean and obese participants
also suggests that this may occur in vivo.
An important ﬁnding of this study in healthy asymptomatic
individuals is that EL mass concentrations are positively
associated with CAC, a measure of subclinical atherosclerosis
in humans, even after controlling for cardiovascular risk
factors, plasma lipids, and vasoactive medications. The
observation that EL tends to be a stronger predictor of
CAC in women than in men could reﬂect the fact that HL
activity is lower in women [52]. In the presence of less HL
activity, EL might have a greater relative inﬂuence on HDL
metabolism and atherosclerosis.
Importantly, our analysis was based on measurement of EL
mass, not EL activity. LPL and HL activity are generally
measured in post-heparin plasma by assaying their triglycer-
ide lipase activity. However, EL has much less triglyceride
lipase activity compared with these enzymes. Therefore, EL
activity in human plasma will need to be assessed based on its
phospholipase activity and will require differentiation of EL-
speciﬁc activity from other sources of phospholipase activity,
such as HL. The development of a validated assay will allow
determination of the association between EL mass and
activity and EL activity with plasma lipids and atheroscle-
rosis.
In summary, EL mass is present in measurable amounts in
pre-heparin plasma, and increases 3-fold after administration
of heparin. EL concentrations are inversely associated with
total HDL-C concentrations and positively associated with
obesity, triglycerides, fasting glucose, and hypertension,
factors composing the metabolic syndrome. Finally, plasma
EL concentrations are associated with subclinical atheroscle-
rosis independent of all established risk factors, including
plasma lipids. These data support the concept that plasma EL
concentrations may modulate metabolic dyslipidemia and
atherosclerosis. Prospective studies will be needed to deter-
mine if EL is, indeed, a risk factor.
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Patient Summary
Background. Atherosclerosis (clogging of the arteries), characterized by
progressive injury to blood vessels in critical organs such as the heart
and the brain, can lead to heart attacks and strokes. It is the most
common cause of death and loss of quality of life in Western societies
and is on the rise worldwide. In addition to high blood pressure,
diabetes, obesity, and smoking, cholesterol levels are a major risk factor
for atherosclerosis. Twenty years ago, we thought that high cholesterol
was bad, but now we know that there several types of cholesterol,
including ‘‘good cholesterol’’ (called HDL-C) and ‘‘bad cholesterol’’ (LDL-
C), and that healthy people have high levels of HDL-C and low levels of
LDL-C.
Why Was This Study Done? The researchers who did this study and
others had previously found a link between a molecule call endothelial
lipase (EL) and atherosclerosis in mice. In mice, EL seems to decrease the
levels of HDL-C, the ‘‘good cholesterol,’’ and to make the mice more
prone to atherosclerosis. Overall, mice with lower levels of EL seemed to
be better off. The question was whether EL levels influenced cholesterol
levels and atherosclerosis in humans as well. Human studies until now
had searched for a connection between different variants of the EL gene
and atherosclerosis, but had not yielded clear answers.
What Did the Researchers Do and Find? In this study, the researchers
directly measured levels of EL in the blood of over 800 human
participants and looked for links with cholesterol levels and other
atherosclerosis risk factors. They found that, just as in mice, higher blood
concentrations of EL are linked with lower levels of HDL-C (the effect was
clear but not very large). They also found that higher concentrations of
EL were linked with other risk factors for atherosclerosis such as obesity
and hypertension. Finally, they found that raised EL concentrations were
linked with signs of early atherosclerosis in the participants, and this link
held true even when they corrected for all other risk factors, i.e., when
they compared people who had the same weight, blood pressure, and
cholesterol levels.
What Does This Mean? The study found a link in humans between high
EL concentrations in the blood, low HDL-C levels, and early stages of
atherosclerosis. This suggests (but does not prove) that EL concen-
trations influence the risk of atherosclerosis and could be used to predict
an individual’s risk. Proving that EL levels predict risk can only be done in
so-called ‘‘prospective studies’’ (studies that look forward over time,
rather than go backward). Such studies would measure EL blood
concentrations in a large number of people now, subdivide them into
groups that differed in their EL levels but not in any other factors known
to influence atherosclerosis, and then check years later whether there are
differences in atherosclerosis, heart attacks, and strokes between the
groups. Such studies will take time. While they are ongoing, it seems
worth exploring the possibility that treatments to reduce EL levels might
help prevent atherosclerosis.
Where Can I Find More Information Online? Patient information pages
from the National Lipid Association: http://www.lipid.org/clinical/
patients/
Medline Plus pages on vascular diseases: http://www.nlm.nih.gov/
medlineplus/vasculardiseases.html
A collection of atherosclerosis resources for patients and families from
the Guam Medical Library:
http://guam-dl.slis.ua.edu/patientinfo/cardiology/cardiovascular/
atherosclerosis.html
Atherosclerosis page at the University of Maryland Web site: http://www.
umm.edu/cardiac/athero.htm
American Heart Association Web site:
http://www.americanheart.org
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